#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small intestine adenocarcinoma Angelman's syndrome Pemphigus Primitive neuroectodermal tumour Infertility female Cytokine release syndrome Oesophageal atresia Carcinoid tumour Chronic myeloid leukaemia Neuropathic arthropathy Hereditary neuropathic amyloidosis Cystic fibrosis gastrointestinal disease Atypical haemolytic uraemic syndrome Cutaneous T-cell lymphoma stage II Acute leukaemia More trials…

    Learn about Rare Diseases

    Burkitt’s lymphoma Prader-Willi syndrome – Basic Information Adrenocortical carcinoma – Diagnostics Alveolar rhabdomyosarcoma Hyperoxaluria Alexander disease Ewing’s sarcoma – Life with Disease Congenital hypotransferrinaemia – Treatment Congenital nephrogenic diabetes insipidus – Diagnostics Proteus syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    AZD1163 SODIUM SELENITE PENTAHYDRATE Phentermine Enx-101 Ucart20X22 Pimozide Lasofoxifene INSULIN DETEMIR Alfacalcidol S095035 Garadacimab Cetrorelix Captopril Rbl027.2 VTX2735 SODIUM Anthoxanthum Odoratum Ep0042 ULEFNERSEN Avalglucosidase Alfa Gemcitabine Hydrochloride More therapies…

    Learn about Your Condition

    Micrographic skin surgery Syphilis Post cardiac arrest syndrome Neuroendocrine carcinoma Behcet's syndrome Peritoneal dialysis Cerebral amyloid angiopathy Partial seizures Brain neoplasm Injection site pain Primary hyperthyroidism Femoral neck fracture Delirium Bone metabolism disorder Optic glioma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Nemolizumab
    Austria Belgium Bulgaria Czechia Estonia France +8

  • Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Vascular Endothelial Growth Factor Receptor 3 Extracellular Domains 1-3 Fused To A Igg1 Fc Fragment
    • Aflibercept
    Austria Bulgaria Croatia Czechia Estonia France +10

  • Study of Pembrolizumab with Cisplatin or Carboplatin and Pemetrexed for Patients with Resectable Malignant Pleural Mesothelioma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Italy

  • Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal cancer metastatic
    • Oesophageal carcinoma
    Investigated Drugs:
    • Domvanalimab
    • Zimberelimab
    • Calcium Folinate
    France Greece Hungary Italy Lithuania Poland +3

  • Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cytarabine
    • Rituximab
    Italy

  • Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Sonelokimab
    Austria Bulgaria Germany Hungary Italy Norway +2

  • Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    4 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Etrasimod Arginine
    Austria Belgium Bulgaria Croatia Czechia Denmark +9

  • Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Axatilimab
    • Methylprednisolone
    • Ruxolitinib
    Belgium Germany Italy Spain

  • Study of Patritumab Deruxtecan for Patients with Previously Treated Metastatic or Locally Advanced EGFR-Mutated Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Patritumab Deruxtecan
    Belgium France Germany Italy The Netherlands Spain

  • Study on Vedolizumab for Patients with Active Ulcerative Colitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Vedolizumab
    Belgium France Italy The Netherlands Poland
Previous Page
1 … 43 44 45 46 47 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!